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Hypothesis: Uric acid, nephron number, and the pathogenesis
of essential hypertension.
Background. Essential hypertension affects more than 25%
of the world’s population. Genetic, physiologic, and epidemio-
logic studies provide clues to its origins, but a clear understand-
ing has been elusive. Recent experimental and clinical studies
have implicated uric acid in the onset of essential hypertension.
Methods. In a retrospective chart review, we identified 95
children with confirmed, new onset hypertension, and evaluated
the cause of hypertension and parental history of hypertension,
birth weight, and serum uric acid. In an open-label, cross-over
trial we treated 5 children with confirmed essential hypertension
with allopurinol as single treatment agent, and screened for
change in blood pressure by casual and ambulatory methods.
In tissue culture experiments, we evaluated the effect of uric
acid on glomerular endothelial cell function.
Results. Elevation of serum uric acid is related to the onset
of essential hypertension in children, reduced birth weight, and
endothelial dysfunction. Normalization of uric acid appears to
ameliorate new onset essential hypertension.
Conclusion. These findings, combined with animal model
data, support the hypothesis that uric acid has a key role in
the pathogenesis of early onset essential hypertension, and may
unify some of the disparate theories of the origins of essential
hypertension.
Essential hypertension affects 25% of the world’s pop-
ulation and is a major cause of stroke, congestive heart
failure, end-stage renal disease, and myocardial infarc-
tion. Renal transplantation studies in animals and hu-
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mans strongly suggest that the underlying cause resides
in the kidney [1, 2]. Most evidence is consistent with
Guyton’s hypothesis [3] that at similar levels of blood
pressure, individuals with essential hypertension have a
physiologic defect in the efficiency of renal sodium excre-
tion. It is likely that in some cases the defect is mediated
by genetic alterations in the expression or regulation of
transport mechanisms involved in sodium reabsorption
or excretion [4]. Genetic linkage studies, however, reveal
few significant genetic correlations with essential hyper-
tension [5, 6], suggesting the genetic contributions to hy-
pertension are sufficiently complex to defy currently used
techniques, and/or nongenetic factors contribute in sus-
ceptible individuals.
A favored hypothesis proposed by Brenner [7] is that
hypertension may result from a congenital reduction in
nephron number. Barker and others have identified a
strong relationship between intrauterine growth retarda-
tion (IUGR) and low birth weight with the later devel-
opment of hypertension in the adult [8, 9]. IUGR and
low birth weight correlate with impaired renal develop-
ment [10] and reduced nephron number at birth [11, 12].
A recent autopsy study found that subjects with essential
hypertension had nearly 50% fewer nephrons than con-
trol subjects [13]. A reduced nephron number results in
compensatory hyperfiltration, which may lead to progres-
sive nephron loss over time [14], decreasing ultrafiltration
surface area, and limiting sodium excretion [15]. While
reduced nephron number will decrease filtered sodium
load, few kidney transplant donors develop hypertension,
even after many years of follow-up [16], challenging this
pathway as a major pathogenic mechanism.
Any proposal for the development of essential hyper-
tension must also take into account the nearly universal
presence of arteriolosclerosis and tubulointerstitial in-
flammation within the kidneys of hypertensive subjects
[17, 18]. While many have proposed that these changes
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result from hypertension, there is some accruing evidence
that the lesions precede the development of hypertension
[19]. Goldblatt has even suggested that primary develop-
ment of the arteriolosclerosis was the cause of hyperten-
sion, and that the mechanism involved the induction of
renal ischemia [20]. While this hypothesis had been
largely discarded, recent studies provide evidence in sup-
port of this pathway [21].
In this paper, we present the hypothesis, with prelim-
inary evidence, that an elevation in uric acid may have
a key role in the pathogenesis of essential hypertension,
and we also present evidence that it may be a factor for
the presence of a lower nephron number in subjects with
essential hypertension.
HYPERURICEMIA AS A MECHANISM FOR
ESSENTIAL HYPERTENSION
Epidemiologic evidence
An elevation in serum uric acid has consistently been
found to predict the development of hypertension [22–
24]. Population studies have also shown that the fre-
quency of hypertension increases in a continuous and
graded fashion with increasing quartile of serum uric acid
[25]. The strongest association of uric acid with hyperten-
sion is with new onset essential hypertension [26]. In a
recent study of adolescents with hypertension, a serum
uric acid of >5.5 mg/dL was observed in 89% of essen-
tial hypertensive subjects (N = 63), in 30% of those with
secondary hypertension (N = 40), and in 0% of control
subjects (N = 40) or “white coat” hypertensives (N =
22) [26]. The correlation of uric acid with systolic blood
pressure in control subjects and subjects with primary hy-
pertension was continuous and strong (r = 0.8, P < 0.001),
and not explained by obesity or decreased renal function
[26]. Interestingly, the association between hypertension
and serum uric acid is less strong in adults. In the Fram-
ingham data, it attenuates with subsequent examinations
[27, 28]. This suggests that an elevation in uric acid may
be more important in the development of hypertension
rather than in its maintenance.
Experimental evidence in animals
The most direct evidence in support of uric acid as a
cause of hypertension is the observation that rats made
mildly hyperuricemic develop the clinical syndrome of
essential hypertension, in which they manifest hyperten-
sion, renal arteriolar disease, renal vasoconstriction, with
minimal reduction in renal function [29–35]. Prevention
of hyperuricemia with allopurinol (a xanthine oxidase
inhibitor) or with benziodarone (a uricosuric) also pre-
vented the development of hypertension.
The hypertension in this model was driven by two
major mechanisms. The initial hypertension was evident
particularly under low-salt dietary conditions, and was
associated with an impairment in plasma nitric oxide
(NO) concentration [36] and with a reduction in both
macula densa nitric oxide synthase-1 (NOS-1) and renal
endothelial NOS-3 [29, 37]. Administration of L-arginine
(a substrate for NO synthesis) attenuates the increase in
blood pressure, confirming the role of decreased NO in
the induction of uric acid–mediated hypertension. The
increase in blood pressure was also associated with stim-
ulation of juxtaglomerular renin, and could be blocked
by an angiotensin-converting enzyme inhibitor or an an-
giotensin II type I receptor antagonist [29, 30].
Over time, however, the hypertension becomes in-
dependent of the serum uric acid levels. The mecha-
nism appears to involve the development of subtle renal
microvascular disease [33]. Specifically, hyperuricemic
rats developed an arteriolopathy of the afferent arte-
riole that could be shown to occur independently of
blood pressure [30]. The possibility that the arteriolopa-
thy was mediated by a direct action of uric acid is
supported by in vitro studies showing that uric acid
could induce cell proliferation, as well as the stimu-
lation of cyclooxygenase-2, the local renin angiotensin
system, growth factors (platelet-derived growth factor,
or PDGF), and chemokines (monocyte chemoattractant
protein-1) [33, 35, 38, 39]. After the formation of the
arteriolar lesion, the rats developed salt-sensitive hy-
pertension independent of the uric acid level [33]. This
is consistent with other animal models in which the
development of renal arteriolar disease results in salt-
sensitive hypertension. The mechanism for this pathway
has been recently reviewed and consists of tubular is-
chemia with the recruitment of inflammatory cells (T cells
and macrophages) that release oxidants and angiotensin
II, which cause cortical vasoconstriction and sodium
retention [40–44]. Blockade of the vascular and inflam-
matory processes can ameliorate the hypertension [21,
39–44].
Experimental evidence in man
Proof that uric acid may be involved in the pathogen-
esis of hypertension in man must await studies examin-
ing the effect of lowering uric acid on blood pressure.
Because the experimental studies suggest that lower-
ing uric acid will be most likely to show an effect on
blood pressure before the development of significant re-
nal microvascular disease, we initiated an open-label pilot
study in which adolescents with newly diagnosed essen-
tial hypertension were treated with allopurinol for one
month followed by a 4-week washout period. As shown in
Figure 1, reduction of serum uric acid level from a mean
of 6.9 mg/dL to 3.3 mg/dL with 200 mg of allopurinol
twice daily significantly reduced casual blood pressure
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Fig. 1. Allopurinol lowers uric acid and
blood pressure in adolescents with essential
hypertension. Children were recruited from
the Hypertension program at Texas Chil-
dren’s Hospital. The 5 children had con-
firmation of their hypertension by in-clinic,
home, and ABP monitoring, and were diag-
nosed with essential hypertension as previ-
ously described. Inclusion criteria were newly
diagnosed essential hypertension, no current
or previous antihypertensive medications or
diuretics, serum uric acid >6.0mg/dL, and
normal renal function (Schwartz calculation
>90cc/min/1.73m2). Subjects were treated
with allopurinol at 200 mg bid for 4 weeks
followed by a 6-week washout period off
medications. No other interventions, such as
exercise or dietary modifications, were made.
Casual and ABPM measurements were per-
formed immediately before treatment, at the
end of 4 weeks of treatment while still on al-
lopurinol, and 6 weeks after discontinuing the
allopurinol. Serum uric acid was measured
at the 3 BP measurement visits, as well as
one week after the initiation of allopurinol to
confirm a >40% decrease in serum uric acid
levels. Numbers in parentheses are P values,
calculated by paired t test, in comparison to
pretreatment data. The study was open label,
and compliance was assessed uric acid levels.
No adverse events occurred during the trial.
The study was approved by the Baylor Insti-
tutional Review Board.
measurements, and led to normalization of blood pres-
sure by ambulatory blood pressure monitoring (ABPM)
criteria in 4 of 5 subjects. One must be careful in the
interpretation of the pilot study because of a potential
placebo effect; nevertheless, the initial results provide a
strong rationale for a future placebo-controlled study.
The above studies support the hypothesis that an eleva-
tion in uric acid may have a major role in the pathogenesis
of hypertension. Specifically, the studies suggest that uric
acid causes endothelial dysfunction, vascular disease, and
a ‘salt-resistant’ hypertension, which then progresses to a
renal-dependent pathway of salt-sensitive hypertension.
This provides a rationale to perform studies to determine
whether lowering uric acid can either prevent hyperten-
sion or treat early hypertension.
The relationship of serum uric acid and a congenital
reduction in nephron number
An important question is how to converge the uric acid
hypothesis with the extensive studies linking congenital
reduction in nephron number with the risk for future hy-
pertension. To evaluate this further, we first evaluated the
relationship of birth weight with the later development of
hypertension in a retrospective chart review of patients
enrolled in the Hypertension Program at Texas Children’s
Hospital. Patients with primary hypertension were distin-
guished from secondary hypertension, white coat hyper-
tension, and control subjects by extensive workup [26].
As shown in Figure 2A, we found that subjects with pri-
mary hypertension had lower birth weights compared
with control subjects and subjects with secondary or white
coat hypertension. This is consistent with the Brenner
hypothesis and suggests that the congenital reduction in
nephron number is specific for primary hypertension, as
opposed to secondary causes. We also examined the re-
lationship of birth weight with the degree of serum uric
acid at presentation. As shown in Figure 2B, we found
that the lower the birth weight, the higher the serum uric
acid (r = 0.42, P = .0008). This shows that a low birth
weight predicts the serum uric acid in adolescence, and
suggests a causal relationship. In this regard, micropunc-
ture studies in uninephrectomized rats show that a re-
duction in nephron number will result in an increase in
absolute proximal reabsorption [45]; because uric acid
reabsorption is linked to proximal sodium reabsorption,
this might provide a mechanism for the development of
hyperuricemia. But then, what causes the congenital re-
duction in nephron number?
Barker has suggested that maternal factors passed to
the fetus during pregnancy may be responsible for the
later development of hypertension [8]. Indeed, the fa-
milial predisposition toward essential hypertension is
stronger if the mother has hypertension in most [46–48],
but not all [49], studies. This was also evident in the co-
hort we studied, in which a history of hypertension in the
mother was twice as common as a history of hypertension
in the father (Table 1).
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Fig. 2. Serum uric acid in adolescents with essential hypertension cor-
relates inversely with the birth weight of the individual. In a retrospec-
tive chart review, the charts of patients enrolled in the Hypertension
Program at Texas Children’s Hospital were screened for birth weight.
Ninety-five children were identified who had recorded birth weight,
serum uric acid, and confirmed diagnosis of hypertension (diagnostic
protocol described previously). The mean, standard error, and stan-
dard deviation of patient’s birth weights as a function of their diagnosis
are shown (A). The correlation analysis for birth weight and serum uric
acid at the time of diagnosis of hypertension is shown (B).
Table 1. Family history of hypertension in adolescents diagnosed
with hypertension in the Texas Children’s Hospital Hypertension
Program
Primary Secondary White coat Control
N = 75 N = 63 N = 33 N = 45
Mother 41.3% 26.9% 27.3% 11.1%
Father 22.7% 12.7% 36.4% 22.2%
Both parents 22.7% 17.4% 6.1% 8.9%
Neither 13.3% 42.8% 30.3% 57.8%
We would like to propose that the ‘maternal factor’
that causes a reduction in nephron number is a factor
that inhibits endothelial cell proliferation, and that one
of the principal mediators may be uric acid. Support
for this hypothesis is provided by several lines of argu-
ment. First, it is known that glomerular development in
newborn rats (which continues into the neonatal period)
can be inhibited by the administration of anti-vascular
endothelial growth factor (VEGF) antibody, a potent
inhibitor of endothelial cell proliferation [50]. The sus-
ceptibility of the nephrons to inhibitors of endothelial
cell proliferation, as opposed to other organs late in preg-
nancy, may relate to the relative uniqueness of nephron
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Fig. 3. Inhibition of glomerular endothelial cells by uric acid. Rat
glomerular endothelial cells (passage 15, gift of Dr. Stephen Adler,
Valhalla, NY) were growth arrested for 24 hours by serum starvation
[in Dulbecco’s modified Eagle’s medium (DMEM) with 0.5% fetal
bovine serum (FBS)] on 6-well plates. Cells were then incubated in
DMEM (0.5% FBS) with or without uric acid (5 mg/dL) for 24 hours.
3H-thymidine (1 lCi/mL) was added to the culture plates 6 hours be-
fore harvest to quantify the glomerular endothelial cell proliferation.
Thymidine uptake was assayed by liquid scintillation counting. Studies
were performed in triplicate and the cells were all incubated at uniform
conditions of 37◦C, with 5% CO2. Comparison was by ANOVA with
Bonferroni correction. Physiologic levels of uric acid can significantly
inhibit the proliferation of glomerular endothelial cells, a step required
for nephronogenesis during late pregnancy, consistent with the possi-
bility that maternal elevations in serum uric acid could contribute to
reduced nephron number in the fetus.
development, which is known to primarily occur in the
third trimester [11]. Second, uric acid becomes a candi-
date to block nephron development because it potently
inhibits human umbilical vein endothelial cell prolifera-
tion in vitro [51]. We have also found that soluble uric
acid blocks rat glomerular endothelial cell proliferation
under low serum conditions (Fig. 3). Nitric oxide (NO)
is also a trophic factor for endothelial cells, and uric acid
is an inhibitor of NO production in vitro [51], in animals
[36], and in man [52]. Indeed, studies in humans also have
found that uric acid levels correlate inversely with plasma
NO and with acetylcholine-dependent vasodilation [53,
54], and blockade of uric acid production with allopuri-
nol also improves endothelial-dependent vasodilation in
patients with congestive heart failure or diabetes [55, 56].
Third, uric acid is a small substance that is known to freely
pass into the fetal circulation, where it has been shown to
correlate with the development of IUGR and low birth
weight [57].
Perhaps the best evidence is provided by studies in
preeclampsia. This is a condition characterized by a
marked rise in serum uric acid in the mother during the
third trimester, elevated levels of uric acid in the fetus,
and a high frequency of IUGR and low birth weights.
Not surprisingly, children of preeclamptic mothers have
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an increased frequency for the later development of hy-
pertension [58, 59]. The rise in uric acid that occurs in
the third trimester in preeclampsia corresponds well with
the period when nephron development is impaired in
low-birth-weight infants [10]. Higher uric acid levels in
preeclamptic mothers correlate more closely with worse
fetal outcome than maternal blood pressure [60, 61], and
the uric acid level in the fetal cord blood in preeclamptic
and control infants has been found to inversely corre-
late with the birth weight [57]. It was also recently re-
ported that women with gestational hypertension and
hyperuricemia without proteinuria have evidence of en-
dothelial dysfunction and deliver growth-retarded babies
[62, 63].
Endothelial dysfunction as a general mechanism linking
low nephron number to hypertension
The above studies have focused on the role of uric acid
as a mediator of endothelial dysfunction, low nephron
number, and the development of hypertension; however,
it is likely that other mediators may also play an important
role. For example, in preeclampsia, a major factor that is
present in the circulation is sFLT-1, which is a circulating
inhibitor of VEGF [64]. Recently, strong evidence has
been provided that sFLT-1 may be largely responsible
for the development of hypertension and renal disease in
preeclampsia [64]. Another circulating factor that causes
endothelial dysfunction is asymmetric dimethylargi-
nine (ADMA), which blocks NO production. Savvidou
et al found that maternal ADMA levels correlated with
both defective endothelial-dependent vasodilation in the
mother and with low birth weights in preeclampsia [65].
Endothelial dysfunction is also common in essential hy-
pertension [66]. Furthermore, early essential hyperten-
sion is highly associated with an elevated uric acid level
[26], as well as elevated levels of sFLT-1 [67] and ADMA
[68]. These studies thus suggest that factors that impair
endothelial function might account for both the presence
of a low nephron number, as well as possibly directly lead-
ing to the development of hypertension. In this regard,
we have reported that the administration of an NO syn-
thase inhibitor to rats will lead to the development of an
afferent arteriolopathy and tubulointerstitial inflamma-
tion that results in persistent salt-sensitive hypertension
[42]. Hence, a factor such as uric acid, which causes both
endothelial dysfunction and vascular smooth muscle cell
proliferation, would be expected to cause the renal lesion
that would result in the development of hypertension.
We propose a general pathway linking uric acid to the
development of hypertension (Fig. 4). First, we suggest
that an elevated uric acid in the mother, particularly dur-
ing the third trimester, may cross into the placenta along
with other substances that may interfere with endothelial
dysfunction to cause IUGR and impair nephron develop-
ment. The increase in maternal uric acid could be caused
by the development of gestational hypertension (such as
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Fig. 4. Hypothetical mechanism by which hyperuricemia leads to re-
duced nephron number and hypertension. Elevated maternal serum
uric acid levels (or other inhibitors of endothelial cell proliferation)
cross the placenta into the developing fetus during nephron develop-
ment. Increases in fetal uric acid levels during the third trimester inhibit
endothelial proliferation, a necessary step of nephron development,
and reduce the final nephron number at birth. The lower congenital
nephron number may lead to hyperuricemia during adolescence as a
consequence of increased proximal reabsorption, and hyperuricemia
may also result from genetic and environmental factors linked to mater-
nal hyperuricemia. The hyperuricemia causes endothelial dysfunction
and hyper-reninemia, which induces a salt-resistant hypertension. The
combination of hyperuricemia with the hemodynamic consequences of
low nephron number leads to subtle renal injury (arteriolopathy and in-
terstitial inflammation) and the development of a renal-dependent, salt-
sensitive hypertension that eventually becomes independent of serum
uric acid levels.
related to pre-existing hypertension, obesity, or renal dys-
function, all conditions associated with higher uric acid
levels in the nonpregnant patient) or from the develop-
ment of preeclampsia. Once born, the child will have a
decreased nephron number, with relative hyperfiltration
occurring in his/her glomeruli. It remains possible that the
low nephron number might itself predispose to the devel-
opment of hyperuricemia as a consequence of an increase
in proximal tubular reabsorption [69], which might stim-
ulate uric acid reabsorption (which is linked to sodium
reabsorption in the proximal tubule). It also seems likely
that an elevation of uric acid in the child could occur from
genetic, familial, or environmental (such as diet shared
by mother and child) mechanisms, for as mentioned, the
mothers of these children frequently themselves mani-
fest underlying hyperuricemia, obesity, and/or hyperten-
sion. Thus, these children would be expected to have
evidence for higher serum uric acid levels and/or evidence
of endothelial dysfunction during childhood and before
their development of hypertension. Consistent with this
hypothesis, children with low birth weights do have evi-
dence for both impaired endothelial cell vasodilation (at
age 9 to 11) [46] and decreased capillary recruitment [47].
Subjects at risk for developing essential hypertension are
also more likely to have impaired microvascular dilation
and increased capillary rarefaction [70], and an increased
serum uric acid [22, 23]. Eventually, the combination of
the low nephron number, coupled with the concurrent
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endothelial dysfunction, leads to the development of ini-
tially a salt-resistant hypertension (driven by endothe-
lial dysfunction and renin activation), followed by a
salt-sensitive hypertension (driven by kidney ischemia
mediated by the arteriolopathy and interstitial inflam-
mation). Indeed, there is evidence that the presence of a
low nephron number and hyperuricemia are additive in
their ability to induce renal injury [71], and both condi-
tions also independently result in glomerular hyperten-
sion [14, 31]. It is also possible that a marked increase in
serum uric acid could induce hypertension independently
of nephron number, as suggested by the experimental
studies in animals [29, 30].
The presence of maternal factors that inhibit endothe-
lial and glomerular development could also explain two
confusing observations regarding essential hypertension.
Keller et al [13] observed that men with essential hy-
pertension have fewer nephrons; however, renal trans-
plant donors who also have reduced nephron mass do
not develop hypertension more frequently than the pop-
ulation at large [16]. If the cause of congenital reduction
in nephron number is a diffusible inhibitor of nephron
development acting through altered endothelial and vas-
cular smooth muscle function, transplant donor nephrec-
tomy would not be expected to cause the same results.
Second, maternal factors that modify genetically con-
ferred risk would not be detectable on genetic linkage
analysis or microarray expression analysis, and would in
part explain the difficulties in establishing the genetic
basis for essential hypertension.
CONCLUSION
We present a hypothesis linking endothelial dysfunc-
tion, driven by an elevated uric acid and other substances,
to cause the congenital reduction in nephron number that
is associated with the later development of hypertension.
We also suggest that an elevation in uric acid may be a
critical initiator of the renal mechanisms leading to the
development of essential hypertension via both its ability
to cause endothelial dysfunction and renin activation, and
by causing intrarenal lesions that mediate the develop-
ment of salt-sensitivity. Further studies are necessary to
prove different aspects of this pathway.
ACKNOWLEDGMENTS
Support for this paper was provided by an NIH K-23 award DK-
064587 (DF), by NIH HL-68607 (RJ) and a George O’Brien Center P50-
DK064233-01 (RJ). The clinical studies described in this manuscript
were reviewed and approved by the Baylor College of Medicine In-
stitutional Review Board. Oral and written informed consent and in-
formed assent (as appropriate) was obtained from all subjects. The data
as present are free of identifying markers to maintain confidentiality.
Reprint requests to Daniel I. Feig, M.D., Ph.D., Renal Section, MC3-
2482, Department of Pediatrics, Baylor College of Medicine, Houston,
TX 77030.
E-mail: dfeig@bcm.tmc.edu
REFERENCES
1. DAHL LK, HEINE M: Primary role of renal homografts in setting
chronic blood pressure levels in rats. Circ Res 36:692–696, 1975
2. CURTIS JJ, LUKE RG, DUSTAN HP, et al: Remission of essential hy-
pertension after renal transplantation. N Engl J Med 309:1009–1015,
1983
3. GUYTON AC, COLEMAN TG, COWLEY AV, JR., et al: Arterial pres-
sure regulation. Overriding dominance of the kidneys in long-term
regulation and in hypertension. Am J Med 52:584–594, 1972
4. LIFTON RP: Molecular genetics of human blood pressure variation.
Science 272:676–680, 1996
5. CAULFIELD M, MUNROE P, PEMBROKE J, et al: Genome-wide mapping
of human loci for essential hypertension. Lancet 361:2118–2123,
2003
6. PROVINCE MA, KARDIA SL, RANADE K, et al: A meta-analysis of
genome-wide linkage scans for hypertension: The National Heart,
Lung and Blood Institute Family Blood Pressure Program. Am J
Hypertens 16:144–147, 2003
7. BRENNER BM, GARCIA DL, ANDERSON S: Glomeruli and blood pres-
sure. Less of one, more the other? Am J Hypertens 1:335–347,
1988
8. BARKER DJ: The fetal origins of adult hypertension. J Hypertens
Suppl 10:S39–44, 1992
9. BARKER DJ, OSMOND C, GOLDING J, et al: Growth in utero, blood
pressure in childhood and adult life, and mortality from cardiovas-
cular disease. BMJ 298:564–567, 1989
10. KONJE JC, BELL SC, MORTON JJ, et al: Human fetal kidney morphom-
etry during gestation and the relationship between weight, kidney
morphometry and plasma active renin concentration at birth. Clin
Sci (Lond) 91:169–175, 1996
11. HINCHLIFFE SA, LYNCH MR, SARGENT PH, et al: The effect of
intrauterine growth retardation on the development of renal
nephrons. BJOG 99:296–301, 1992
12. HUGHSON M, FARRIS AB, DOUGLAS-DENTON R, et al: Glomeru-
lar number and size in autopsy kidneys: The relationship to birth
weight. Kidney Int 63:2113–2122, 2003
13. KELLER J, ZIMMER G, MALL G, et al: Nephron number in patients
with primary hypertension. N Engl J Med 348:101–118, 2003
14. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake
and the progressive nature of kidney disease: The role of hemody-
namically mediated glomerular injury in the pathogenesis of pro-
gressive glomerular sclerosis in aging, renal ablation, and intrinsic
renal disease. N Engl J Med 307:652–659, 1982
15. KIMURA G, BRENNER BM: A method for distinguishing salt-sensitive
from non-salt-sensitive forms of human and experimental hyperten-
sion. Curr Opin Nephrol Hypertens 2:341–349, 1993
16. GOLDFARB DA, MATIN SF, BRAUN WE, et al: Renal outcome 25 years
after donor nephrectomy. J Urol 166:2043–2047, 2001
17. MORITZ A, OLDT M: Ateriolar sclerosis in hypertensive and nonhy-
pertensive individuals. Am J Pathol 13:679–728, 1937
18. SOMMERS S, RELMAN R, SMITHWICK R: Histologic studies of kidney
biopsy specimens from patients with hypertension. Am J Pathol 34,
1958
19. TRACY RE: Renovasculopathies of hypertension and the rise of
blood pressure with age in blacks and whites. Semin Nephrol 16:126–
133, 1996
20. GOLDBLATT H, LYNCH J, HANZAL R, SUMMERVILLE W: Studies on ex-
perimental hypertension: I. The production of persistent elevation
of systolic blood pressure by means of renal ischemia. J Exp Med
59:347–379, 1934
21. JOHNSON RJ, HERRERA-ACOSTA J, SCHREINER GF, RODRIGUEZ-
ITURBE B: Subtle acquired renal injury as a mechanism of salt-
sensitive hypertension. N Engl J Med 346:913–923, 2002
22. SELBY JV, FRIEDMAN GD, QUESENBERRY CP, JR.: Precursors of essen-
tial hypertension: Pulmonary function, heart rate, uric acid, serum
cholesterol, and other serum chemistries. Am J Epidemiol 131:1017–
1027, 1990
23. JOSSA F, FARINARO E, PANICO S, et al: Serum uric acid and hyperten-
sion: The Olivetti heart study. J Hum Hypertens 8:677–681, 1994
24. MASUO K, KAWAGUCHI H, MIKAMI H, et al: Serum uric acid
and plasma norepinephrine concentrations predict subsequent
weight gain and blood pressure elevation. Hypertension 42:474–480,
2003
Feig et al: Uric acid, nephron number, and pathogenesis of essential hypertension 287
25. KLEIN R, KLEIN BE, CORNONI JC, et al: Serum uric acid. Its rela-
tionship to coronary heart disease risk factors and cardiovascular
disease, Evans County, Georgia. Arch Intern Med 132:401–410, 1973
26. FEIG DI, JOHNSON RJ: Hyperuricemia in childhood primary hyper-
tension. Hypertension 42:247–252, 2003
27. BRAND FN, MCGEE DL, KANNEL WB, et al: Hyperuricemia as a
risk factor of coronary heart disease: The Framingham Study. Am
J Epidemiol 121:11–18, 1985
28. KANNEL WB: Metabolic risk factors for coronary heart disease
in women: Perspective from the Framingham Study. Am Heart J
114:413–419, 1987
29. MAZZALI M, HUGHES J, KIM YG, et al: Elevated uric acid increases
blood pressure in the rat by a novel crystal-independent mechanism.
Hypertension 38:1101–1106, 2001
30. MAZZALI M, KANELLIS J, HAN L, et al: Hyperuricemia induces a pri-
mary renal arteriolopathy in rats by a blood pressure-independent
mechanism. Am J Physiol Renal Physiol 282:F991–997, 2002
31. SANCHEZ-LOZADA LG, TAPIA E, AVILA-CASADO C, et al: Mild hy-
peruricemia induces glomerular hypertension in normal rats. Am J
Physiol Renal Physiol 283:F1105–1110, 2002
32. NAKAGAWA T, MAZZALI M, KANG DH, et al: Hyperuricemia causes
glomerular hypertrophy in the rat. Am J Nephrol 23:2–7, 2003
33. WATANABE S, KANG DH, FENG L, et al: Uric acid hominoid evolution
and the pathogenesis of salt-sensitivity. Hypertension 40:355–360,
2002
34. KANELLIS J, WATANABE S, LI JH, et al: Uric acid stimulates monocyte
chemoattractant protein-1 production in vascular smooth muscle
cells via mitogen-activated protein kinase and cyclooxygenase-2.
Hypertension 41:1287–1293, 2003
35. KANG DH, NAKAGAWA T, FENG L, JOHNSON RJ: Nitric oxide mod-
ulates vascular disease in the remnant kidney model. Am J Pathol
161:239–248, 2002
36. FINCH J, MU W, PARRA G, et al: Hyperuricemia induces endothelial
dysfunction in rats. Proceedings of the 36th Annual Meeting of the
American Society of Nephrology, San Diego, CA, 2003
37. MAZZALI M, KIM YG, SUGA S, et al: Hyperuricemia exacer-
bates chronic cyclosporine nephropathy. Transplantation 71:900–
905, 2001
38. RAO GN, CORSON MA, BERK BC: Uric acid stimulates vascu-
lar smooth muscle cell proliferation by increasing platelet-derived
growth factor A-chain expression. J Biol Chem 266:8604–8608, 1991
39. KANELLIS J, NAKAGAWA T, HERRERA-ACOSTA J, et al: A single path-
way for the development of essential hypertension. Cardiol Rev
11:180–196, 2003
40. JOHNSON RJ, GORDON KL, SUGA S, et al: Renal injury and salt-
sensitive hypertension after exposure to catecholamines. Hyperten-
sion 34:151–159, 1999
41. FRANCO M, TAPIA E, SANTAMARIA J, et al: Renal cortical vasocon-
striction contributes to development of salt-sensitive hypertension
after angiotensin II exposure. J Am Soc Nephrol 12:2263–2271, 2001
42. QUIROZ Y, PONS H, GORDON KL, JR., et al: Immune cells play a role in
the pathogenesis of salt-sensitive hypertension resulting from short-
term nitric-oxide synthase inhibition in the rat. Am J Physiol Renal
Physiol 281:38–47, 2001
43. ANDOH TF, JOHNSON RJ, LAM T, BENNETT WM: Subclinical renal
injury induced by transient cyclosporine exposure is associated with
salt-sensitive hypertension. Am J Transplant 1:222–227, 2001
44. KANG DH, KIM YG, ANDOH TF, et al: Post-cyclosporine-mediated
hypertension and nephropathy: Amelioration by vascular endothe-
lial growth factor. Am J Physiol Renal Physiol 280:F727–736, 2001
45. HERRERA-ACOSTA J, JOHNSON RJ: Unpublished observations, 2003
46. MURAKAMI K, KOJIMA S, KIMURA G, et al: The association between
salt sensitivity of blood pressure and family history of hypertension.
Clin Exp Pharmacol Physiol 20(Suppl):61–63, 1992
47. FRIEDMAN GD, SELBY JV, QUESENBERRY CP, JR., et al: Precursors
of essential hypertension: Body weight, alcohol and salt use, and
parental history of hypertension. Prev Med 17:387–402, 1988
48. FUENTES RM, NOTKOLA IL, SHEMEIKKA S, et al: Familial aggrega-
tion of blood pressure: A population-based family study in eastern
Finland. J Hum Hypertens 14:441–445, 2000
49. BURKE V, GRACEY MP, BEILIN LJ, MILLIGAN RA: Family history as
a predictor of blood pressure in a longitudinal study of Australian
children. J Hypertens 16:269–276, 1998
50. KITAMOTO Y, TOKUNAGA H, TOMITA K: Vascular endothelial growth
factor is an essential molecule for mouse kidney development:
Glomerulogenesis and nephrogenesis. J Clin Invest 99:2351–2357,
1997
51. KANG DH, JOHNSON RJ: Uric acid induces C-reactive protein ex-
pression via upregulation of angiotensin type I receptor in vascular
endothelial and smooth muscle cells. J Am Soc Nephrol 14:F-PO336,
2003
52. WARING W, WEBB D, MAXWELL S: Effect of local hyperuricemia on
endothelial function in the human forearm vascular bed. Br J Clin
Pharmacol 48:511, 2000
53. KANABROCKI EL, THIRD JL, RYAN MD, et al: Circadian relationship
of serum uric acid and nitric oxide. JAMA 283:2240–2241, 2000
54. MAXWELL AJ, BRUINSMA KA: Uric acid is closely linked to vascular
nitric oxide activity. Evidence for mechanism of association with
cardiovascular disease. J Am Coll Cardiol 38:1850–1858, 2001
55. DOEHNER W, SCHOENE N, RAUCHHAUS M, et al: Effects of xan-
thine oxidase inhibition with allopurinol on endothelial function
and peripheral blood flow in hyperuricemic patients with chronic
heart failure: Results from 2 placebo-controlled studies. Circulation
105:2619–2624, 2002
56. BUTLER R, MORRIS AD, BELCH JJ, et al: Allopurinol normalizes
endothelial dysfunction in type 2 diabetics with mild hypertension.
Hypertension 35:746–751, 2000
57. CHANG FM, CHOW SN, HUANG HC, et al: The placental transfer and
concentration difference in maternal and neonatal serum uric acid
at parturition: Comparison of normal pregnancies and gestosis. Biol
Res Pregnancy Perinatol 8:35–39, 1987
58. SHAMMAS AG, MAAYAH JF: Hypertension and its relation to re-
nal function 10 years after pregnancy complicated by pre-eclampsia
and pregnancy induced hypertension. Saudi Med J 21:190–192,
2000
59. ABER GM: Intrarenal vascular lesions associated with pre-
eclampsia. Nephron 21:297–309, 1978
60. SAGEN N, HARAM K, NILSEN ST: Serum urate as a predictor of fetal
outcome in severe pre-eclampsia. Acta Obstet Gynecol Scand 63:71–
75, 1984
61. REDMAN CW, BEILIN LJ, BONNAR J, WILKINSON RH: Plasma-urate
measurements in predicting fetal death in hypertensive pregnancy.
Lancet 1:1370–1373, 1976
62. POWERS R, WOO K, PATRICK T, et al: Gestational hypertension
and hyperuricemia even without proteinuria identifies women with
increased cellular fibronectin. J Soc Gynecol Investig 10:A247,
2003
63. WOO K, POWERS R, PATRICK T, et al: Gestational hypertension and
hypertension without proteinuria is an indicator of poor fetal out-
come. J Soc Gynecol Investig 10:A241, 2003
64. MAYNARD SE, MIN JY, MERCHAN J, et al: Excess placental solu-
ble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial
dysfunction, hypertension, and proteinuria in preeclampsia. J Clin
Invest 111:649–658, 2003
65. SAVVIDOU MD, HINGORANI AD, TSIKAS D, et al: Endothelial dysfunc-
tion and raised plasma concentrations of asymmetric dimethylargi-
nine in pregnant women who subsequently develop pre-eclampsia.
Lancet 361:1511–1517, 2003
66. TADDEI S, SALVETTI A: Endothelial dysfunction in essential hyper-
tension: Clinical implications. J Hypertens 20:1671–1674, 2002
67. BELGORE FM, LIP GY, BAREFORD D, et al: Plasma levels of vascular
endothelial growth factor (VEGF) and its receptor, Flt-1, in haema-
tological cancers: A comparison with breast cancer. Am J Hematol
66:59–61, 2001
68. SURDACKI A, NOWICKI M, SANDMANN J, et al: Reduced urinary ex-
cretion of nitric oxide metabolites and increased plasma levels of
asymmetric dimethylarginine in men with essential hypertension. J
Cardiovasc Pharmacol 33:652–658, 1999
69. SHIRLEY DG, WALTER SJ: Acute and chronic changes in renal func-
tion following unilateral nephrectomy. Kidney Int 40:62–68, 1991
70. NOON JP, WALKER BR, WEBB DJ, et al: Impaired microvascular di-
latation and capillary rarefaction in young adults with a predisposi-
tion to high blood pressure. J Clin Invest 99:1873–1879, 1997
71. KANG DH, NAKAGAWA T, FENG L, et al: A role for uric acid in
the progression of renal disease. J Am Soc Nephrol 13:2888–2897,
2002
